1. What is the Orange Healthcare CD55 (PNH Marker) Test?
It is a specialised laboratory test used to assess CD55 protein expression on blood cells. CD55 protects cells from complement-mediated damage, and its reduced or absent expression may be associated with paroxysmal nocturnal haemoglobinuria.
2. Why is the CD55 (PNH Marker) Test performed?
The test is performed to investigate suspected PNH in individuals experiencing unexplained haemolytic anaemia, dark-coloured urine, blood clots, or unexplained reductions in blood cell counts. It may be included in a broader PNH flow cytometry panel.
3. What does a positive CD55 result indicate?
A CD55-positive result generally indicates that the tested cells express the protective CD55 protein. Normal CD55 expression is expected in healthy blood cells, although CD55 positivity alone cannot completely exclude a small PNH clone.
4. What does a negative CD55 result indicate?
Reduced or absent CD55 expression may indicate a population of cells deficient in this protective protein, which can occur in PNH. However, CD55 deficiency alone is insufficient to confirm PNH, and additional markers such as CD59 and FLAER are required for accurate evaluation.
5. Is fasting required for the Orange Healthcare CD55 (PNH Marker) Test?
Fasting is generally not required. Patients can usually eat and drink normally before sample collection unless additional investigations require specific preparation.
6. What sample is required for the CD55 (PNH Marker) Test?
A peripheral blood sample collected in an EDTA tube is commonly required. CD55 expression may be assessed using flow cytometry. For reliable PNH detection, modern testing generally includes FLAER and additional GPI-linked markers on granulocytes and monocytes, along with CD59 assessment on red blood cells.